Literature DB >> 3894199

Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagogastric varices: a prospective controlled randomized trial.

K J Paquet, H Feussner.   

Abstract

A prospective randomized controlled clinical trial was performed in 43 consecutive histologically proved cirrhotic patients with endoscopically proved actively bleeding esophageal varices. Twenty-two were randomly selected to have esophageal tamponade with the Sengstaken-Blakemore tube, and 21 were selected to have endoscopic sclerosis of the esophageal wall. The two groups were similar in demographic, clinical and laboratory data. Bleeding was controlled by the Sengstaken-Blakemore tube in 16 of 22 patients (73%) and by endoscopic sclerosis in 20 of 21 (95%). Among those controlled by the Sengstaken-Blakemore tube, seven (44%) rebled and three (43%) were again controlled by the Sengstaken-Blakemore tube; in the endoscopic sclerosis group, four (20%) rebled and three (75%) were controlled. Thus, hemorrhage was definitively controlled in 52% of patients and 66% of bleeding episodes in the Sengstaken-Blakemore tube group and in 90% of patients and 92% of bleeding episodes in the endoscopic sclerosis group. The definite control of hemorrhage was significantly better in the endoscopic sclerosis group (p less than 0.01). The Sengstaken-Blakemore tube patients received no definitive therapy after bleeding had been controlled. Within 30 days, six patients (27%) in the Sengstaken-Blakemore tube group had died compared to 2 (10%) in the endoscopic sclerosis group which is statistically significant (p less than 0.01) in favor of endoscopic sclerosis. The frequency of complications was similar in the two groups. Endoscopic sclerosis patients received serial endoscopic sclerosis after bleeding had been stopped during the whole period of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894199     DOI: 10.1002/hep.1840050409

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

1.  UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology.

Authors:  R Jalan; P C Hayes
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

2.  Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system.

Authors:  N Yuki; M Kubo; Y Noro; N Hayashi; H Fusamoto; A Ito; M Masuzawa; T Kamada
Journal:  Gastroenterol Jpn       Date:  1990-10

Review 3.  The management of an episode of variceal bleeding.

Authors:  A E Gimson; D Westaby
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 4.  Portal hypertension--25 years of progress.

Authors:  B R MacDougall; D Westaby; L A Blendis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 5.  The use of sclerotherapy for the management of oesophageal varices in portal hypertension.

Authors:  J Terblanche
Journal:  Surg Endosc       Date:  1988       Impact factor: 4.584

6.  Better control of esophageal variceal bleeding by sclerotherapy followed by surgery.

Authors:  H Ashida; A Nishioka; M Fukuda; Y Kotoura; Y Ishikawa; J Utsunomiya
Journal:  Jpn J Surg       Date:  1990-05

7.  Immediate endoscopic sclerosis of bleeding esophageal varices. A prospective evaluation over five years.

Authors:  K J Paquet; J F Kalk; P Koussouris
Journal:  Surg Endosc       Date:  1988       Impact factor: 4.584

8.  Rigid versus fiberoptic endoscopic injection sclerotherapy. A prospective randomized controlled trial in patients with bleeding esophageal varices.

Authors:  P C Bornman; D Kahn; J Terblanche; C Worthley; R A Spence; J J Krige
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

Review 9.  Sclerotherapy for bleeding esophageal varices after randomized trials.

Authors:  D A Lieberman
Journal:  West J Med       Date:  1986-10

Review 10.  Endoscopic treatments for portal hypertension.

Authors:  Gin-Ho Lo
Journal:  Hepatol Int       Date:  2017-11-07       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.